罗醇通过向JAK2/STAT3信号通路来增强尼替尼在细胞癌中的疗效
Zongrun Sun1, Zixuan Chen1, Yuesong Cai2
1Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, No.1111 Xian Xia Road, Shanghai, 200336, China.
Naunyn-Schmiedeberg's archives of pharmacology
|March 5, 2026
概括
烯醇通过克服耐药性来增强细胞癌 (RCC) 的苏尼替尼的疗效. 这种植物化合物向关键信号通路,为癌治疗提供了一个有前途的新策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 细胞癌 (RCC) 是最常见的癌.
- 对氨酸激酶抑制剂 (TKIs) 的耐药性,如苏尼提尼,限制了RCC治疗的有效性.
研究的目的:
- 调查Citronellol在RCC中增强逊尼提尼布敏感性的潜力.
- 阐明Citronellol对RCC的影响背后的分子机制.
主要方法:
- 网络药理学分析以确定Citronellol目标.
- 使用RCC细胞系 (786-O和A498) 的体外实验.
- 西部斑点分析以评估信号通路调制.
主要成果:
- 罗醇抑制了RCC细胞的增殖,迁移和诱导的亡.
- 罗醇显著降低了sunitinib的IC50值,并增强了其抗癌作用.
- 烯醇抑制了EGFR,JAK2和STAT3的酸化.
结论:
- 罗醇通过抑制JAK2/STAT3信号通路来增强沙尼替尼在RCC中的疗效.
- 这种组合策略显示出克服癌中TKI耐药性的前景.
- 罗醇代表了一种改善RCC治疗结果的潜在治疗剂.
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K


